Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis
复制标题
DOI：
10.1016/s0264-410x(98)00227-8
复制
发表时间：
1998-12-01
期刊：
影响因子：
5.5
通讯作者：
Olin, P
中科院分区：
文献类型：
--
作者：
Storsaeter, J;Hallander, HO;Olin, P
与安慰剂相比，家庭接触百日咳杆菌后，对典型百日咳的疫苗效力估计无细胞五组分疫苗为75.4%，无细胞两组分疫苗为42.4%，美国许可全细胞疫苗为28.5%。Logistic回归分析显示，暴露前血清中抗Pertactin、菌毛2/3和百日咳毒素抗体的存在与临床保护之间存在统计学意义上的相关性。在最近的瑞典NIAID赞助的疗效试验中，被证明高效的多组分百日咳疫苗比效果较差的疫苗诱导出更高的针对Pertactin和2/3菌毛的抗体水平。抗百日咳菌毛、抗百日咳菌毛和抗PT抗体可作为百日咳多组分无细胞疫苗和全细胞疫苗保护的替代标志物。(C)1998爱思唯尔科学有限公司。保留所有权利。
Vaccine efficacies against typical pertussis after household exposure to Bordetella pertussis were estimated to be 75.4% for an acellular five-component vaccine, 42.4% for an acellular two-component vaccine and 28.5%, for a licensed US whole cell vaccine, compared to placebo. Logistic regression analyses demonstrated statistically significant correlations between clinical protection and the presence of IgG antibodies against pertactin, fimbriae 2/3 and pertussis toxin in pre-exposure sera. Multicomponent pertussis vaccines of proven high efficacy in recent Swedish NIAID-sponsored efficacy trials induced higher antibody levels against pertactin and fimbriae 2/3 than less efficacious vaccines. Anti-pertactin, anti-fimbriae 2/3, and anti-PT may be used as surrogate markers of protection for multicomponent acellular and whole-cell vaccines against pertussis. (C) 1998 Elsevier Science Ltd. All rights reserved.